Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tenofovir
Drug ID BADD_D02154
Description Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate.[A37693] In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog.[A37693] The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in the form of [tenofovir disoproxil] and [tenofovir alafenamide] in order to obtain oral bioavailability.[A18473, A178360]
Indications and Usage Tenofovir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older. It is also indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.
Marketing Status Prescription
ATC Code J05AF07
DrugBank ID DB14126
KEGG ID D01982
MeSH ID D000068698
PubChem ID 464205
TTD Drug ID D0D9HW
NDC Product Code 55773-4041
Synonyms Tenofovir | 9-(2-Phosphonylmethoxypropyl)adenine | 9-PMPA (tenofovir) | 9-(2-Phosphonomethoxypropyl)adenine | 9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer | 9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer | Tenofovir Disoproxil Fumarate | Disoproxil Fumarate, Tenofovir | Fumarate, Tenofovir Disoproxil | Tenofovir Disoproxil | Disoproxil, Tenofovir | 9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098 | (R)-9-(2-phosphonylmethoxypropyl)adenine | Viread
Chemical Information
Molecular Formula C9H14N5O4P
CAS Registry Number 147127-20-6
SMILES CC(CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypokalaemia14.05.03.002--
Hypophosphataemia14.04.03.001--
Immune system disorder10.02.01.001--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Lactic acidosis14.01.01.002--Not Available
Multiple fractures15.08.02.005; 12.04.02.009--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Myopathy15.05.05.001--Not Available
Nasopharyngitis11.01.13.002; 22.07.03.002--Not Available
Nausea07.01.07.001--
Nephrogenic diabetes insipidus20.05.03.010; 14.05.07.002--Not Available
Nervous system disorder17.02.10.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Osteomalacia20.01.01.002; 15.02.03.001; 14.04.04.001--Not Available
Pain08.01.08.004--
Pancreatitis07.18.01.001--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Polyuria20.02.03.002--Not Available
Proteinuria20.02.01.011--
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Renal tubular disorder20.05.03.004--Not Available
Renal tubular necrosis20.01.07.003--Not Available
Rhabdomyolysis15.05.05.002--
Sinusitis22.07.03.007; 11.01.13.005--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages